Doctors Without Borders urges Gilead to rethink its hepatitis C strategy in Ukraine

The latest battle over access to medicines is taking place in Ukraine, where Doctors Without Borders is urging Gilead Sciences to drop a court action that, if successful, would prevent a generic version of the Sovaldi hepatitis C treatment from remaining available. In a Sept. 5 letter released publicly Tuesday, Gilead was asked to “reconsider its business strategy in high-burden, middle-income countries, especially Ukraine,” since its strategies “threaten

Middle-Income Countries consider voiding hepatitis C drug patents

Physician, patient, and health justice groups including the Initiative for Medicines, Access and Knowledge (I-MAK) are mounting legal challenges to Gilead Sciences' patent to sofosbuvir in several middle-income countries including Argentina, Brazil, China, Russia and Ukraine. Read more...http://www.nytimes.com/2015/05/20/business/high-cost-of-hepatitis-c-drug-prompts-a-call-to-void-its-patents.html...